Part B: A PHASE 1/2a, STUDY OF SAFETY, TOLERABILITY, PHARMACOKINECTS AND PHARMACODYNAMICS OF CDK-003 (exoIL-12) IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)